Mesoblast Reports Substantial Revenue Growth to US$120M

manilatimes.net · 2026-08-27

RYONCIL Market Share Expands; Phase 3 Back Pain Trial Completes Treatment

TickrTrends take: Mesoblast's achievement of US$120M in revenue represents a significant milestone for the Healthcare sector company as it transitions toward profitability and cash generation. With TickrTrends currently awaiting full valuation on the stock, investors focused on valuation metrics should monitor whether this revenue growth translates into expanding margins and positive cash flow, as these factors will be critical to establishing an appropriate valuation multiple. The company's ability to sustain and accelerate this revenue trajectory will be essential context for any future valuation assessment.

Read the full story at manilatimes.net →